For opportunistic salpingectomy to become widespread and reduce ovarian cancer rates, patients must be aware of the option and request it during other abdominal surgeries. This requires public education campaigns to create demand, complementing surgeon training.
The RUBY trial's presentation on dMMR endometrial cancer used a "cure model" to quantify the likelihood of cure, a paradigm shift in patient communication for advanced solid tumors that offers statistical hope beyond just survival rates.
In dMMR endometrial cancer, data from the RUBY trial shows very few progressions after the first year. This "conditional survival" insight suggests that the current standard of 2-3 years of maintenance immunotherapy may be longer than necessary.
Despite data supporting limited-duration immunotherapy, physicians struggle to stop treatment. Patients in complete remission often view the well-tolerated therapy as a "lifeline," creating psychological barriers to de-escalating care.
A consistent pattern has emerged across new trials in platinum-resistant ovarian cancer (ROSELLA, KEYNOTE-B96, MIRASOL): therapies provide only modest progression-free survival (PFS) but a more substantial overall survival (OS) advantage, suggesting a shared biological effect.
The ROSELLA trial's success in boosting chemotherapy with a glucocorticoid receptor antagonist is thought-provoking. It suggests that routinely used steroids for managing side effects like nausea might inadvertently be diminishing chemotherapy's effectiveness across various cancers.
Driven by T-DXd's high efficacy and the known variability of IHC testing, oncologists are pragmatically retesting HER2-negative tumors and treating HER2-low (1+) patients. This blurs official indications to maximize patient access to a transformative drug.
In the evolving landscape of antibody-drug conjugates (ADCs), the critical factor for sequencing is likely the cytotoxic payload, not just the target antigen. A patient could respond to an ADC with a different payload after progressing on another, even if both target the same protein.